Press Releases and Statements

(PHILADELPHIA) – The Consumer Healthcare Products Association Educational Foundation (CHPAEF) held its 8th Annual Gala last night at The Bellevue Hotel in Philadelphia. The widely attended event brought together more than 350 attendees from 93 companies across the self-care industry. In addition to highlighting CHPAEF’s key 2023 educational initiatives, the event program also included the unveiling of the Foundation’s new name: Health in Hand, and an announcement on the election of Elizabeth Karvonen, Team Lead of the Emerson Group, to serve as Health in Hand’s new board chair. Elizabeth will succeed previous chair Kyle Stenzel, Senior Vice President of Sales and Global Supply Chain for Combe Inc.

“After urging Governor Hochul to recognize the importance of a more balanced approach to this issue, CHPA was disappointed to see this legislation signed into law today, making New York the only state in the country to unnecessarily limit consumers’ access to a broad range of dietary supplements.

(Washington, D.C.) – Consumer Healthcare Products Association (CHPA) Senior Vice President of Regulatory and Scientific Affairs Lisa Parks released the following statement today regarding the U.S. Food and Drug Administration’s

This week, the Consumer Healthcare Products Association (CHPA) hosted its annual Regulatory, Scientific & Quality (RSQ) Conference. This year’s premier gathering of regulatory experts in the consumer healthcare industry was attended by more than 300 participants and included over 60 speakers and panelists.

CHPA released a statement after submitting a Citizen Petition to the U.S. Federal Trade Commission (FTC) urging it to withdraw the Notice of Penalty Offenses Concerning Substantiation of Product Claims.

CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.

CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).

CHPA echoed concerns in a letter sent to the U.S. Food and Drug Administration by U.S. Reps. Bob Latta (OH-05), Debbie Dingell (MI-06), and Dan Crenshaw (TX-02), urging the Agency to ensure the simultaneous marketing provision of its proposed rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use is not included in a final rule.

The Consumer Healthcare Products Association Educational Foundation today released the following statement announcing the 2023 U.S. Self-Care Marketing Awards finalists. Winners will be announced at the Eighth Annual CHPA Educational Foundation Gala on November 15 at The Bellevue Hotel in Philadelphia. Specific awards will recognize the strategic innovation and marketing expertise of CHPA member companies in the OTC medicine, consumer medical device, and dietary supplement industries.

Today, the Consumer Healthcare Products Association (CHPA) submitted comments to the U.S. Food and Drug Administration (FDA) in response to a Citizen Petition from the Environmental Defense Fund (EDF) asking FDA to revoke the use of the colorant titanium dioxide (TiO2) in foods, including dietary supplements.

A recent national survey of adults conducted by the Bullfinch Group for CHPA further sheds light on consumer awareness, experiences, and perceptions of PE.

The Consumer Healthcare Products Association (CHPA) Educational Foundation and Family Dollar today announced the launch of a program to help Family Dollar shoppers make informed, educated choices about choosing and using over-the-counter (OTC) products and dietary supplements.